Quote:

---

I am interested/surprised that there does not seem to be any use of leronlimab in MIS-C. Has anyone seen reports of this? Cytodyn offered free chemokine analysis of MIS-C, presumably with Incelldx panel, but I have not heard of any availing themselves of this opportunity.

---

I don't believe we've heard an update on this, just as surprised as you.

This is all I have:

5/13/2020 Notes (can't guaranteed accuracy):

Quote:

---

Protocols being submitted for children with Kawasaki-like symptoms soon – there are hurdles
The Kawasaki-like protocol will likely consist of three doses, the first by IV infusion

---

5/15/2020 Press Release:
Source Link: https://seekingalpha.com/news/3574944-cytodyn...ent=link-1

Quote:

---

CytoDyn (OTCQB:CYDY) is offering comprehensive cytokine profiling through its diagnostic partner, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19.

These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children.

The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.

---

5/17/2020 Notes (can't guaranteed accuracy):

Quote:

---

CytoDyn has no clinical pediatric studies for leronlimab, so they don’t feel they can ask the FDA for a Compassionate Use program. However, they do want to support pediatricians and institutions that are caring for these children. They may be filing for a Pediatric EIND. The recently announced free testing program is all about measuring RANTES in this cohort. With the number of hospitals now participating in trials, one would think it wouldn't be that difficult to obtain blood samples to prove the existence of RANTES – or not.

---